Zacks Research Upgrades TriSalus Life Sciences (NASDAQ:TLSI) to “Hold”

TriSalus Life Sciences (NASDAQ:TLSI) was upgraded by equities research analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a research report issued on Tuesday,Zacks.com reports.

Several other brokerages also recently commented on TLSI. Canaccord Genuity Group upped their price objective on shares of TriSalus Life Sciences from $11.00 to $12.00 and gave the company a “buy” rating in a research note on Wednesday. Wall Street Zen raised TriSalus Life Sciences from a “sell” rating to a “hold” rating in a research report on Friday, November 28th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of TriSalus Life Sciences in a research report on Monday. Three analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $11.00.

TriSalus Life Sciences Price Performance

Shares of TriSalus Life Sciences stock opened at $7.30 on Tuesday. TriSalus Life Sciences has a one year low of $3.42 and a one year high of $7.70. The business’s 50 day simple moving average is $5.46 and its two-hundred day simple moving average is $5.06. The stock has a market capitalization of $364.71 million, a P/E ratio of -3.61 and a beta of 0.43.

TriSalus Life Sciences (NASDAQ:TLSI) last issued its earnings results on Thursday, November 13th. The company reported ($0.96) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($0.79). The firm had revenue of $11.57 million for the quarter, compared to analysts’ expectations of $11.76 million. Sell-side analysts expect that TriSalus Life Sciences will post -1.55 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. Bank of America Corp DE lifted its position in TriSalus Life Sciences by 1.8% during the second quarter. Bank of America Corp DE now owns 188,906 shares of the company’s stock valued at $1,030,000 after buying an additional 3,374 shares during the period. Connective Capital Management LLC increased its stake in shares of TriSalus Life Sciences by 12.8% in the 2nd quarter. Connective Capital Management LLC now owns 32,796 shares of the company’s stock worth $179,000 after acquiring an additional 3,717 shares in the last quarter. Millennium Management LLC increased its stake in shares of TriSalus Life Sciences by 17.7% in the 3rd quarter. Millennium Management LLC now owns 35,612 shares of the company’s stock worth $166,000 after acquiring an additional 5,359 shares in the last quarter. Police & Firemen s Retirement System of New Jersey purchased a new position in TriSalus Life Sciences during the 2nd quarter valued at about $29,000. Finally, JPMorgan Chase & Co. boosted its stake in TriSalus Life Sciences by 35,804.8% during the second quarter. JPMorgan Chase & Co. now owns 7,540 shares of the company’s stock worth $41,000 after acquiring an additional 7,519 shares in the last quarter. Institutional investors own 2.58% of the company’s stock.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.